8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 20, 2026·SEC
Material company update
Feb 27, 2026·SEC
Jupiter Neurosciences, Inc.(JUNS)Earnings, Financials & Key Ratios
JUNS•NASDAQ
$0.28
Price updated Jun 27, 2026
AboutJupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.Show more
- Revenue$22K
- EBITDA-$9M-291.5%
- Net Income-$9M-254.4%
- EPS (Diluted)-0.25-194.8%
- Gross Margin80.59%
- EBITDA Margin-39359.87%
- Operating Margin-40873.19%
- Net Margin-39662.77%
- ROE-738.83%-1163.5%
JUNS Price & Volume
Jupiter Neurosciences, Inc. (JUNS) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Losses Threaten Clinical Viability
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
Key Thesis Takeaways
- Jupiter Neurosciences remains in a precarious pre-commercial stage, characterized by negligible revenue generation and a reliance on external financing to sustain clinical development.
- The firm's inability to achieve operating leverage, evidenced by a negative 105.2% operating margin in 2026Q1, suggests that ongoing R&D and administrative costs will continue to erode shareholder value.
- Investors should monitor the company's critical liquidity position, as the combination of negative equity and a current ratio of 0.51 indicates a high probability of further dilutive capital raises.
Verdict Logic
Negative: The company's current ratio of 0.51 and negative equity of $2.8 million suggest an imminent risk of insolvency or severe shareholder dilution that outweighs potential clinical upside.
JUNS Growth Metrics
Jupiter Neurosciences, Inc. (JUNS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-54.57%
3 Years-54.62%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-175.25%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-153.69%
Return on Capital
10 Years-414.12%
5 Years-414.12%
3 Years-414.12%
Last Year-754.53%
Peers Comparison
Key metrics vs top competitors for Jupiter Neurosciences, Inc. (JUNS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.28 | $10.16M | -1.12 | — | -39662.77% | -738.83% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $25.32 | $4.34B | 11.06 | 11.87% | 34.3% | 35.65% | — | |
| $3.73 | $64.48M | -2.78 | — | -1070.26% | — | — | |
| $4.34 | $17.12M | -0.17 | — | — | -381.01% | — | |
| $23.57 | $1.74B | 7.14 | 18.52% | 118.91% | 47.59% | — |
Compare JUNS vs Peers
Jupiter Neurosciences, Inc. (JUNS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
JUNS SEC Filings & Documents
Jupiter Neurosciences, Inc. (JUNS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when JUNS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
JUNS Frequently Asked Questions
Jupiter Neurosciences, Inc. (JUNS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Jupiter Neurosciences, Inc.'s revenue?
Jupiter Neurosciences, Inc. (JUNS) reported $0.0M in revenue for fiscal year 2025.
Is JUNS profitable?
Jupiter Neurosciences, Inc. (JUNS) reported a net loss of $9.2M for fiscal year 2025.
Dividend & Returns
What is JUNS's return on equity?
Jupiter Neurosciences, Inc. (JUNS) has a return on equity (ROE) of -738.8%. Negative ROE indicates the company is unprofitable.
What is Jupiter Neurosciences, Inc.'s free cash flow?
Jupiter Neurosciences, Inc. (JUNS) had negative free cash flow of $5.8M in fiscal year 2025, likely due to heavy capital investments.